Trial Profile
A Multicentre, Observational, Prospective Study to Assess the Safety profile of Rituximab in combination with chemotherapy in Patients With B cell-lineage Chronic Lymphocytic Leukaemia (B-CLL).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2014
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Antineoplastics
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms MABERYC
- Sponsors Roche
- 07 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Feb 2014 Planned End Date changed from 1 Jan 2014 to 1 Feb 2014 as per ClinicalTrials.gov record.
- 23 May 2013 Planned End Date changed from 1 Jun 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.